The Glass Ceiling: Examining the Advancement of Women in the Domain of Athletic Administration

The “glass ceiling” is a metaphor for examining gender disparities between men and women within the workplace. Such disparities are particularly visible in athletic administration. This literature review evaluates specific leadership characteristics and their relationship to gender stereotyping in Sport Management. Because athletic administration is a male dominated domain, there appears to be discrimination against women, creating a gender gap that prevents the advancement of women into top-level managerial positions

The glass ceiling: Examining leadership perceptions within the domain of athletic administration

The glass ceiling is a metaphor for examining gender disparities between men and women within the workplace. The disparity is particularly dominate in the domain of athletic administration. This study evaluates specific leadership characteristics and their relationship to gender stereotyping. It also examines perceptions that individuals have on leadership based off because athletic administration is specifically a male dominated domain there appears to be discrimination against women inducing a gender gap, and stunting their advancement into top level managerial positions

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Background Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear. Methods RADICALS-HD was an international randomised controlled trial to test the efficacy of ADT used in combination with postoperative radiotherapy for prostate cancer. Key eligibility criteria were indication for radiotherapy after radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to radiotherapy alone (no ADT) or radiotherapy with 6 months of ADT (short-course ADT), using monthly subcutaneous gonadotropin-releasing hormone analogue injections, daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as distant metastasis arising from prostate cancer or death from any cause. Standard survival analysis methods were used, accounting for randomisation stratification factors. The trial had 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 80% to 86% (hazard ratio [HR] 0·67). Analyses followed the intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov, NCT00541047. Findings Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61–69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 9·0 years (IQR 7·1–10·1), metastasis-free survival events were reported for 268 participants (142 in the no ADT group and 126 in the short-course ADT group; HR 0·886 [95% CI 0·688–1·140], p=0·35). 10-year metastasis-free survival was 79·2% (95% CI 75·4–82·5) in the no ADT group and 80·4% (76·6–83·6) in the short-course ADT group. Toxicity of grade 3 or higher was reported for 121 (17%) of 737 participants in the no ADT group and 100 (14%) of 743 in the short-course ADT group (p=0·15), with no treatment-related deaths. Interpretation Metastatic disease is uncommon following postoperative bed radiotherapy after radical prostatectomy. Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Background Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain. Methods RADICALS-HD was a randomised controlled trial of ADT duration within the RADICALS protocol. Here, we report on the comparison of short-course versus long-course ADT. Key eligibility criteria were indication for radiotherapy after previous radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to add 6 months of ADT (short-course ADT) or 24 months of ADT (long-course ADT) to radiotherapy, using subcutaneous gonadotrophin-releasing hormone analogue (monthly in the short-course ADT group and 3-monthly in the long-course ADT group), daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as metastasis arising from prostate cancer or death from any cause. The comparison had more than 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 75% to 81% (hazard ratio [HR] 0·72). Standard time-to-event analyses were used. Analyses followed intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov , NCT00541047 . Findings Between Jan 30, 2008, and July 7, 2015, 1523 patients (median age 65 years, IQR 60–69) were randomly assigned to receive short-course ADT (n=761) or long-course ADT (n=762) in addition to postoperative radiotherapy at 138 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 8·9 years (7·0–10·0), 313 metastasis-free survival events were reported overall (174 in the short-course ADT group and 139 in the long-course ADT group; HR 0·773 [95% CI 0·612–0·975]; p=0·029). 10-year metastasis-free survival was 71·9% (95% CI 67·6–75·7) in the short-course ADT group and 78·1% (74·2–81·5) in the long-course ADT group. Toxicity of grade 3 or higher was reported for 105 (14%) of 753 participants in the short-course ADT group and 142 (19%) of 757 participants in the long-course ADT group (p=0·025), with no treatment-related deaths. Interpretation Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative radiotherapy. For individuals who can accept the additional duration of adverse effects, long-course ADT should be offered with postoperative radiotherapy. Funding Cancer Research UK, UK Research and Innovation (formerly Medical Research Council), and Canadian Cancer Society

Stakeholder’s Perceptions of Needs, Abilities, & Quality of Life of Individuals with Severe & Persistent Mental Illness

Introduction: Approximately 1 in 5 adults (44.7 million individuals) were living with any kind of mental illness in the United States in 2016 (SAMHSA, 2016), but only 19.2 million of those individuals received mental health treatment during that period. Of those, 10.4 million adults (4.2 % of the general adult population), were estimated to have a serious and persistent mental illness (SPMI), but only 6.7 million of those individuals (64%) received mental health treatment in that same year (SAMHSA, 2016). In Florida, the prevalence of mental illness is estimated to be 660,000 (H.R. 8029, 2018). Yet, in terms of services for individuals with mental illness, and compared to other states, Florida’s ranking slid from 49th to 50th place in the past two years with a per capita expenditure of $39.55. SPMI affects individuals’ ability to function and to participate in valued roles and occupations, but recovery is attainable with appropriate interventions and services. This study aimed to understand factors that facilitate and those that hinder the recovery process through the perceptions of individuals with SMPI and of staff members providing services to them. Methodology: This was a retrospective study of qualitative data collected through individual and focus group interviews by two research teams between 2016 and 2017. A clubhouse model drop-in center and residential facilities of a mental health center in central Florida provided the sampling frame. Sample size: There were 44 participants in the final sample (31 clients, 13 staff). Results: Results reflected findings from the literature, indicating the personal nature of recovery, the importance of occupation (doing), identity (being), and kinship (belonging) in recovery, and how these have been impacted by cuts in funding and resources

Investigating the Algodones Dune Field of Southern California II : Using Geospatial Techniques

Color poster with text, images, and photographsThe Eastern Algodones Dunes, located in the Sonoran Desert, Imperial county, Southern California, stretch 72 kilometers and are 9.7 kilometers in width. The dunes were hypothesized to be a result of sediment blown from ancient Lake Cahuilla and are characterized by distinct regions: Glamis Beach, Gordon's Well, Buttercup, Midway, and Patton's Valley. The purpose of the research was to create a digital elevation model (DEM) of the sand starved dune complex by collecting aerial imagery using a DJI Phantom-4PG UAV. To improve overlap and tie points, the aerial imagery has a 75% front lap and a 65% side lap. The flight was flown at 50 meters above ground level and took 20 swaths overhead. To enhance the accuracy of the DEM, ten ground control points (GCPs) were collected using a REACH RS+ RTK GNSS receiver. In addition, a topographic survey was conducted using a TopCon laser leveler to more accurately geometrically correct the collected ground penetrating radar transects.University of Wisconsin--Eau Claire Office of Research and Sponsored Program

Shattering the concrete ceiling: exploring the moderating effects of mass media messages as it relates to the perceived self-efficacy of African-American women

Past research has shown that there are few positive ethnically diverse role models in American society (Hackett & Betz, 1981). African-American women have identified the lack of racially identical role models as a significant barrier to attaining leadership positions within Corporate America. A cross-sectional survey was administered to explore how mass media images depicting counter-stereotypical images of African-American role models affect the self-efficacy beliefs of African-American women (195 respondents, 51%). The researcher also examined the participant’s ability to cope with stress and their reported level of career aspirations as predictors of their level of identification with the potential role model. The results indicated that African-American women have lower levels of both self-efficacy and career aspirations than women of other races (187 respondents, 49%). The results also indicated that the participant’s ability to cope with stress and level of career aspirations predicated their level of identification. Furthermore, the study found that a potential role models race significantly influenced the participants level of identification. This research will foster social change by identifying an effective approach to combating historical stereotypes that lower the self-efficacy of African-American women. Increasing the self-efficacy of African-American women could advance opportunities for minority women’s leadership and reduce the leadership gap in Corporate America. (Published By University of Alabama Libraries

Risk of COVID-19 after natural infection or vaccinationResearch in context

Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health

Risk of COVID-19 after natural infection or vaccinationResearch in context

Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health